Kinfo
Drugs Made In America Acquisition Corp. Rights logo

Drugs Made In America Acquisition Corp. Rights

DMAARNASDAQ·US · USD
$0.11
+0.01 (+5.83%)
Prices as of November 12, 2026 · market closed

Price

Key statistics

Valuation
Market cap2.29M USD
Enterprise value0.00 USD
Trailing P/E0.00
Forward P/E0.00
PEG ratio0.00
Price / sales0.00
Price / book0.00
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets0.00%
Return on equity0.00%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income6.09M USD
Diluted EPS$0.00
Rev. growth (YoY)0.00%
Balance sheet
Total cash20.28K USD
Total debt350.00K USD
Debt / equity0.00
Current ratio0.02
Book value / share-$0.31
Cash flow (TTM)
Operating cash flow-517.14K USD
Levered free cash flow0.00 USD
Shares & price
Shares outstanding20.40M
Float19.79M
Held by institutions0.00%
Beta0.00
50-day MA$0.00
200-day MA$0.00
52-week high$0.21
52-week low$0.04
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-090.04-0.02−150.00%2026-02-100.961.00+4.17%
About Drugs Made In America Acquisition Corp. Rights

Drugs Made In America Acquisition Corp. Rights is a rights security linked to Drugs Made In America Acquisition Corp., a special purpose acquisition company focused on completing a business combination in the pharmaceutical and healthcare-related sectors. Each right represents a contractual entitlement to receive a fraction of an ordinary share when a qualifying combination is completed, making it part of the company’s capital structure rather than an operating business on its own. The security is designed for investors who hold the company’s units and may be separated for separate trading after issuance. Drugs Made In America Acquisition Corp. uses this rights instrument to support its acquisition-focused model, which centers on identifying and combining with businesses connected to drug manufacturing, life sciences, and related healthcare markets. As a SPAC-related security, it plays a financing and transaction-support role within the broader public markets.

CEO
Ms. Lynn Stockwell
Headquarters
New York, NY, United States

Frequently asked questions about Drugs Made In America Acquisition Corp. Rights